These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 22433611)

  • 101. Diabetes: Efficacy of dapagliflozin associated with renal function.
    Kirk R
    Nat Rev Endocrinol; 2013 Dec; 9(12):688. PubMed ID: 24126478
    [No Abstract]   [Full Text] [Related]  

  • 102. Use of low-dose clinical pharmacodynamic and pharmacokinetic data to establish an occupational exposure limit for dapagliflozin, a potent inhibitor of the renal sodium glucose co-transporter 2.
    Gould JC; Kasichayanula S; Shepperly DC; Boulton DW
    Regul Toxicol Pharmacol; 2013 Oct; 67(1):89-97. PubMed ID: 23851069
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats.
    Devenny JJ; Godonis HE; Harvey SJ; Rooney S; Cullen MJ; Pelleymounter MA
    Obesity (Silver Spring); 2012 Aug; 20(8):1645-52. PubMed ID: 22402735
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Evaluation of the Pharmacokinetic Interaction Between Lobeglitazone and Dapagliflozin at Steady State.
    Jang K; Jeon JY; Moon SJ; Kim MG
    Clin Ther; 2020 Feb; 42(2):295-304. PubMed ID: 31992459
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Exposure-response relationships of dapagliflozin on cardiorenal risk markers and adverse events: A pooled analysis of 13 phase II/III trials.
    Koomen JV; Stevens J; Heerspink HJL
    Br J Clin Pharmacol; 2020 Nov; 86(11):2192-2203. PubMed ID: 32311110
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Developing an injectable co-formulation of two antidiabetic drugs: Excipient impact on peptide aggregation and pharmacokinetic properties.
    Lainé AL; Houvenagel S; Broo A; Jones I; Goodman J; Corkill D; Rose J; Coward S; Sandinge AS; Petrone M; Jermutus L; Santos ALGD
    Int J Pharm; 2020 Feb; 576():119019. PubMed ID: 31911116
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus.
    Whaley JM; Tirmenstein M; Reilly TP; Poucher SM; Saye J; Parikh S; List JF
    Diabetes Metab Syndr Obes; 2012; 5():135-48. PubMed ID: 22923998
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Post-Authorization Safety Study of Hospitalization for Acute Kidney Injury in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting.
    Johannes CB; Beachler DC; Layton JB; Danysh HE; Ziemiecki R; Arana A; Dinh J; Li L; Calingaert B; Pladevall-Vila M; Hunt PR; Chen H; Karlsson C; Johnsson K; Gilsenan A
    Drug Saf; 2023 Feb; 46(2):157-174. PubMed ID: 36528670
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Alternate-day add-on therapy with dapagliflozin in patients with type 2 diabetes mellitus: potential benefits and concerns.
    Singh H; Joshi D; Narula S; Singla M; Rohilla R; Singh J
    Expert Rev Clin Pharmacol; 2022 Feb; 15(2):197-203. PubMed ID: 35274589
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes.
    Chao EC
    Core Evid; 2012; 7():21-8. PubMed ID: 22701099
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Model-Informed Pediatric Dose Selection for Dapagliflozin by Incorporating Developmental Changes.
    Jo H; Pilla Reddy V; Parkinson J; Boulton DW; Tang W
    CPT Pharmacometrics Syst Pharmacol; 2021 Feb; 10(2):108-118. PubMed ID: 33439535
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Effects of dapagliflozin in combination with insulin on cytochrome P450 activities in a diabetes type 1 rat model.
    Sayed N; Murata I; Abdalla O; Kilany O; Dessouki A; Sasaki K
    J Vet Med Sci; 2021 Oct; 83(10):1597-1603. PubMed ID: 34483187
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Pharmaceutical Analytical Profile for Novel SGL-2 Inhibitor: Dapagliflozin.
    Ganorkar SB; Sharma SS; Patil MR; Bobade PS; Dhote AM; Shirkhedkar AA
    Crit Rev Anal Chem; 2021; 51(8):835-847. PubMed ID: 32544345
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes.
    Tahrani AA; Barnett AH
    Diabetes Ther; 2010 Dec; 1(2):45-56. PubMed ID: 22127745
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Dapagliflozin-citric acid cocrystal showing better solid state properties than dapagliflozin.
    Deng JH; Lu TB; Sun CC; Chen JM
    Eur J Pharm Sci; 2017 Jun; 104():255-261. PubMed ID: 28412482
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Patient considerations in the management of type 2 diabetes - critical appraisal of dapagliflozin.
    Salvo MC; Brooks AD; Thacker SM
    Patient Prefer Adherence; 2014; 8():493-502. PubMed ID: 24790417
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Dapagliflozin no longer licensed for type 1 diabetes.
    Drug Ther Bull; 2022 Mar; 60(3):36. PubMed ID: 35017166
    [No Abstract]   [Full Text] [Related]  

  • 118. A Review on the Relationship between SGLT2 Inhibitors and Cancer.
    Lin HW; Tseng CH
    Int J Endocrinol; 2014; 2014():719578. PubMed ID: 25254045
    [TBL] [Abstract][Full Text] [Related]  

  • 119. A precision medicine approach to metabolic therapy for breast cancer in mice.
    Akingbesote ND; Norman A; Zhu W; Halberstam AA; Zhang X; Foldi J; Lustberg MB; Perry RJ
    Commun Biol; 2022 May; 5(1):478. PubMed ID: 35595952
    [TBL] [Abstract][Full Text] [Related]  

  • 120. FDA approval of dapagliflozin for chronic kidney disease: a remarkable achievement?
    Jafar TH
    Lancet; 2021 Jul; 398(10297):283-284. PubMed ID: 34097853
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.